Axios @axios
SCOOP: Vaxart says the COVID vaccine pill it's developing produced immune responses against multiple strains — and showed a mucosal antibody response, which can provide an added layer of protection. The company cited Phase 2 clinical trial data out today. https://t.co/fZPm9NwOPU — PolitiTweet.org